Logo

AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021

Share this

AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021

Shots:

  • The P-III SELECT-COMPARE study evaluates the safety and efficacy of Rinvoq (15 mg- qd) vs PBO and Humira (SC- 40mg- every other week) in a ratio (2:2:1) in adult patients with a mod. to sev. active RA who had an inadequate response to MTX and continued a stable background of MTX
  • The new analysis showed that the therapy maintained high rates of clinical remission & low disease activity compared with Humira @ 3yrs.- the safety profile was consistent with previously reported and in P-III integrated safety analysis- no new safety risks identified up to 4.5yrs.
  • Rinvoq is a selective & reversible JAK inhibitor- approved for three adult rheumatic indications in the EU

  Ref: Abbvie | Image:abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions